Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2015

View Archived Issues

New data presented on the use of [18F]AV14151 as a tau PET tracer

Rigel Pharmaceuticals reviews development pipeline

Phase II data on the coadministration of VT-122 and sorafenib to HCC patients reported

Famitinib improves progression-free survival in CRC patients

Pilot study investigates imaging markers to guide PBT-2 development

Final results of phase I/II study of ISIS-183750 plus irinotecan

Johnson & Johnson reviews progress of fourth quarter 2014

Trovagene and Genomac Research Institute to collaborate on cancer drug resistance prediction trials

Endonovo Therapeutics agrees on equity investment

Athersys and Cell Therapy Catapult receive stem cell therapy grants for acute respiratory condition

Japan Tobacco divulges PDHK inhibitors

Forendo Pharma reports development of 17beta-HSD1 inhibitors

Merck KGaA prepares positive allosteric modulators for infertility

Sichuan Haisco Pharmaceutical presents SGLT2 inhibitors for diabetes

Alligator Bioscience discloses polypeptides binding to CTLA-4 for cancer

FDA grants orphan drug status to intracerebral hemorrhage treatment

APR-246 receives European orphan drug designation

Human abuse liability study of Egalet meets primary endpoint

GSK ships Ebola vaccine candidate to Liberia for phase III trial

FDA clears IND for phase I study of ADXS-HER2

FDA advisory committee recommends approval of Cresemba

Heptares and AstraZeneca advance drug discovery collaboration

Alexza Pharmaceuticals initiates phase II trial of inhaled alprazolam in epilepsy

Sigma-Aldrich and VIB form alliance to supply translational research tools and technologies

Ultimovacs completes share issue to fund development of cancer vaccine UV-1

CytRx reports results from phase IIb trial of aldoxorubicin in soft tissue sarcoma

CHMP issues positive opinion for Prevenar 13 for prevention of pneumococcal pneumonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.